Current Peptide Compliance

Analyzing FDA warning letters issued to peptide manufacturers and compounding pharmacies reveals clear enforcement patterns that every company in this space should understand. The themes that dominated 2024 enforcement actions point directly to the compliance areas that demand the most attention in 2025 and beyond.

Top Citation Categories

The most frequently cited violations in peptide-related warning letters fall into five categories: inadequate sterility assurance for injectable products, insufficient testing of incoming APIs and components, deficient stability data supporting beyond-use dates, failure to report adverse events, and marketing unapproved new drugs under the guise of compounding exemptions or RUO designations.

Sterility Failures Lead the List

For compounders producing sterile peptide preparations, sterility assurance remains the FDA’s primary focus. Warning letters consistently cite inadequate environmental monitoring, failure to validate aseptic processes, insufficient media fill testing, and lack of proper personnel gowning qualification. These are not paperwork issues — they represent genuine patient safety risks that the FDA treats with appropriate severity.

Protecting Your Operation

The most effective defense against a warning letter is proactive compliance. Conduct regular internal audits against FDA inspection criteria, maintain current SOPs that reflect your actual practices, ensure your quality unit has genuine independence and authority, and address deviations promptly with documented corrective actions. Companies that treat compliance as an ongoing program rather than a one-time project are far less likely to face enforcement action.

Worried about FDA inspection readiness? Current Peptide Compliance conducts mock inspections and gap analyses that prepare you for the real thing. Schedule your assessment.